Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations
Mutations within the BCR-ABL kinase domain in imatinib-treated chronic myeloid leukemia
(CML) are the main mechanism of acquired resistance. The early detection of mutations …
(CML) are the main mechanism of acquired resistance. The early detection of mutations …
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate …
S Branford, Z Rudzki, S Walsh, I Parkinson, A Grigg… - Blood, 2003 - ashpublications.org
Imatinib-treated chronic myeloid leukemia (CML) patients with acquired resistance
commonly have detectable BCR-ABL kinase domain mutations. It is unclear whether …
commonly have detectable BCR-ABL kinase domain mutations. It is unclear whether …
The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia
L Wang, K Knight, C Lucas, RE Clark - Haematologica, 2006 - haematologica.org
BCR-ABL kinase mutations may confer resistance to imatinib in patients with chronic
myeloid leukemia (CML), and may predict a poor outcome. We investigated whether rises in …
myeloid leukemia (CML), and may predict a poor outcome. We investigated whether rises in …
Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib
RD Press, SG Willis, J Laudadio… - Blood, The Journal …, 2009 - ashpublications.org
In imatinib-treated chronic myeloid leukemia (CML), secondary drug resistance is often
caused by mutations in the BCR-ABL kinase domain (KD). As alternative therapies are …
caused by mutations in the BCR-ABL kinase domain (KD). As alternative therapies are …
High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy
SG Willis, T Lange, S Demehri, S Otto, L Crossman… - Blood, 2005 - ashpublications.org
Mutations in the kinase domain (KD) of BCR-ABL are the leading cause of acquired imatinib
resistance. In some cases, identical mutations were detected at relapse and in …
resistance. In some cases, identical mutations were detected at relapse and in …
Detection of BCR-ABL mutations and resistance to imatinib mesylate
S Branford, T Hughes - Myeloid leukemia: methods and protocols, 2006 - Springer
The major mechanism of imatinib resistance for patients with chronic myeloid leukemia
(CML) is clonal expansion of leukemic cells with mutations in the Bcr-Abl fusion tyrosine …
(CML) is clonal expansion of leukemic cells with mutations in the Bcr-Abl fusion tyrosine …
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
E Jabbour, H Kantarjian, D Jones, M Talpaz, N Bekele… - Leukemia, 2006 - nature.com
Mutations of the BCR-ABL kinase domain are a common mechanism of resistance to
imatinib in chronic myeloid leukemia. We screened for mutations 171 patients failing …
imatinib in chronic myeloid leukemia. We screened for mutations 171 patients failing …
Analysis of Bcr‐Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P‐loop and T315I mutation is disease phase …
Despite durable responses to imatinib in chronic myeloid leukaemia (CML), mutations in Bcr‐
Abl kinase domain (KD) are known to induce imatinib resistance and cause poor clinical …
Abl kinase domain (KD) are known to induce imatinib resistance and cause poor clinical …
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease …
JS Khorashad, H De Lavallade, JF Apperley… - Journal of clinical …, 2008 - ascopubs.org
Purpose Kinase domain (KD) mutations in the BCR-ABL gene are associated with
resistance to imatinib in chronic myeloid leukemia (CML) but their incidence and prognostic …
resistance to imatinib in chronic myeloid leukemia (CML) but their incidence and prognostic …
Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique
KA Kreuzer, P Le Coutre, O Landt, IK Na… - Annals of …, 2003 - Springer
Recently, various mutations within the Abl sequence have been described that negatively
affect imatinib binding to Bcr/Abl resulting in cellular resistance of chronic myeloid leukemia …
affect imatinib binding to Bcr/Abl resulting in cellular resistance of chronic myeloid leukemia …
相关搜索
- imatinib mesylate bcr abl
- patients with cml pcr analysis
- kinase mutations bcr abl
- patients with cml bcr abl
- pcr analysis bcr abl
- patients with cml primary screen
- primary screen bcr abl
- clinical significance bcr abl
- pcr analysis primary screen
- kinase mutations transcript monitoring
- t315i mutation leukaemia patients
- transcript monitoring bcr abl
- disease phase bcr abl
- t315i mutation bcr abl
- leukaemia patients bcr abl